Table 6A.B.2.6: Soft Tissue Cancers Treatment and Surgical Approaches, United States 2004-2015

Soft Tissue Tumors Treatment Distributions by Diagnosis

		Surgical_Tx		Radiation_Tx		Chemotherapy_Tx		HORMONE_Tx		IMMUNO_Tx	
Histology	Total Cases	N Cases	Proportion Cases Treated	N Cases	Proportion Cases Treated	N Cases	Proportion Cases Treated	N Cases	Proportion Cases Treated	N Cases	Proportion Cases Treated
Neoplasm, malignant	250	93	37%	47	19%	29	12%	1	0%	1	0%
Malignant tumor, giant cell type	7	5	71%	2	29%	1	14%	-	0%	-	0%
Malignant tumor, spindle cell type	92	49	53	19	21	13	14	-	0%	-	0%
Paraganglioma, malignant	69	40	58%	25	36%	16	23%	1	1%	-	0%
Glomus tumor, malignant	39	38	97%	5	13%	1	3%	-	0%	-	0%
Sarcoma, NOS	5,643	3,294	58%	2,028	36%	1,444	26%	30	1%	9	0%
Spindle cell sarcoma	2,795	1,864	67%	1,206	43%	711	25%	11	0%	3	0%
Giant cell sarcoma (excluding bone)	4,179	3,454	83%	2,373	57%	1,015	24%	3	0%	7	0%
Small cell sarcoma	303	190	63%	116	38%	187	62%	1	0%	-	0%
Epithelioid sarcoma	945	755	80%	370	39%	287	30%	5	1%	1	0%
Undifferentiated sarcoma	1,131	952	84%	593	52%	323	29%	4	0%	3	0%
Desmoplastic small round cell tumor	431	198	46%	70	16%	339	79%	5	1%	8	2%
Fibrosarcoma, NOS	1,069	920	86%	436	41%	149	14%	3	0%	1	0%
Fibromyxosarcoma	3,297	3,106	94%	1,581	48%	285	9%	-	0%	3	0%
Infantile fibrosarcoma	73	63	86%	2	3%	36	49%	-	0%	-	0%
Solitary fibrous tumor, malignant	394	342	87%	112	28%	49	12%	-	0%	4	1%
Malignant fibrous histiocytoma	4,965	4,266	86%	2,576	52%	767	15%	10	0%	3	0%
Dermatofibrosarcoma, NOS	2,153	2,062	96%	222	10%	30	1%	-	0%	-	0%
Pigmented dermatofibrosarcoma protuberans	45	45	100%	6	13%	-	0%	-	0%	-	0%
Myxosarcoma	511	448	88%	258	50%	72	14%	-	0%	1	0%
Liposarcoma, NOS	1,767	1,434	81%	502	28%	124	7%	4	0%	1	0%
Liposarcoma, well differentiated	3,286	3,110	95%	564	17%	53	2%	1	0%	1	0%
Myxoid liposarcoma	3,023	2,691	89%	1,574	52%	443	15%	5	0%	-	0%
Pleomorphic liposarcoma	1,061	934	88%	636	60%	236	22%	2	0%	2	0%
Mixed liposarcoma	412	382	93%	216	52%	101	25%	-	0%	2	0%
Dedifferentiated liposarcoma	1,568	1,392	89%	660	42%	246	16%	4	0%	-	0%
Leiomyosarcoma, NOS	8,489	6,738	79%	2,647	31%	1,716	20%	39	0%	7	0%
Epithelioid leiomyosarcoma	194	156	80%	62	32%	50	26%	-	0%	-	0%
Myosarcoma	57	49	86%	15	26%	2	4%	-	0%	-	0%
Myxoid leiomyosarcoma	175	146	86%	70	40%	35	20%	1	1%	-	0%
Rhabdomyosarcoma, NOS	630	268	43%	284	45%	400	63%	11	2%	1	0%
Pleomorphic rhabdomyosarcoma, adult type	405	295	73%	181	45%	192	47%	3	1%	1	0%
Mixed type rhabdomyosarcoma	62	45	73%	36	58%	49	79%	2	3%	-	0%
Embryonal rhabdomyosarcoma, NOS	828	465	56%	480	58%	677	82%	7	1%	2	0%
Spindle cell rhabdomyosarcoma	131	94	72%	58	44%	90	69%	2	2%	-	0%
Alveolar rhabdomyosarcoma	898	377	42%	604	67%	758	84%	12	1%	11	1%
Rhabdomyosarcoma with ganglionic differentiation	9	7	78%	9	100%	8	89%	-	0%	-	0%
Stromal sarcoma, NOS	44	35	80%	9	20%	4	9%	3	7%	-	0%
Malignant rhabdoid tumor	134	85	63%	66	49%	89	66%	2	1%	1	1%
Malignant myoepithelioma	133	122	92%	45	34%	22	17%	-	0%	-	0%
Mesenchymoma, malignant	45	32	71%	14	31%	10	22%	-	0%	-	0%
Synovial sarcoma, NOS	1,509	1,162	77%	779	52%	755	50%	5	0%	5	0%
Synovial sarcoma, spindle cell	1,360	1,133	83%	702	52%	600	44%	6	0%	2	0%
Synovial sarcoma, epithelioid cell	27	19	70%	10	37%	11	41%	-	0%	-	0%
Synovial sarcoma, biphasic	686	617	90%	371	54%	278	41%	3	0%	1	0%
Clear cell sarcoma, NOS (excluding kidney)	426	355	83%	146	34%	83	19%	2	0%	7	2%

Table 6A.B.2.6: Soft Tissue Cancers Treatment and Surgical Approaches, United States 2004-2015

Soft Tissue Tumors Treatment Distributions by Diagnosis

		Surgical_Tx		Radiation_Tx		Chemotherapy_Tx		HORMONE_Tx		IMMUNO_Tx	
Histology	Total Cases	N Cases	Proportion Cases Treated	N Cases	Proportion Cases Treated	N Cases	Proportion Cases Treated	N Cases	Proportion Cases Treated	N Cases	Proportion Cases Treated
Teratoma, malignant, NOS	129	119	92%	2	2%	19	15%	3	2%	-	0%
Hemangiosarcoma	2,235	1,416	63%	851	38%	767	34%	8	0%	9	0%
Hemangioendothelioma, malignant	52	32	62%	11	21%	11	21%	2	4%	-	0%
Epithelioid hemangioendothelioma, malignant	179	126	70%	47	26%	41	23%	2	1%	-	0%
Osteosarcoma, NOS	365	304	83%	103	28%	161	44%	2	1%	-	0%
Chondroblastic osteosarcoma	52	41	79%	15	29%	26	50%	-	0%	-	0%
Juxtacortical chondrosarcoma	6	6	100%	1	17%	-	0%	-	0%	-	0%
Myxoid chondrosarcoma	647	551	86%	241	37%	75	12%	1	0%	1	0%
Mesenchymal chondrosarcoma	117	88	75%	41	35%	57	49%	3	3%	1	1%
Dedifferentiated chondrosarcoma	57	45	79%	16	28%	21	37%	-	0%	-	0%
Malignant giant cell tumor of soft parts	45	39	87%	7	16%	7	16%	-	0%	-	0%
Malignant tenosynovial giant cell tumor	61	57	93%	7	11%	4	7%	-	0%	1	2%
Ewing sarcoma	998	612	61%	409	41%	838	84%	13	1%	2	0%
Peripheral neuroectodermal tumor	262	170	65%	98	37%	208	79%	6	2%	-	0%
Primitive neuroectodermal tumor, NOS	303	196	65%	99	33%	226	75%	4	1%	1	0%
Ganglioneuroblastoma	197	182	95%	16	8%	61	31%	1	1%	10	5%
Neuroblastoma, NOS	679	464	68%	151	22%	469	69%	14	2%	29	4%
Malignant peripheral nerve sheath tumor	2,346	1,962	84%	1,089	46%	589	25%	7	0%	2	0%
Neurilemoma, malignant [obs]	111	87	78%	29	26%	6	5%	-	0%	1	1%
Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation	112	99	88%	48	43%	50	45%	-	0%	-	0%
Alveolar soft part sarcoma	312	221	71%	145	46%	102	33%	-	0%	10	3%
Total Soft Tissue Cancer Tumors	65,015	51,144	79%	26,213	40%	16,524	25%	254	0%	153	0%

Soft Tissue Tumors Surgical Approaches

Surgical Approach	N Cases	Cases Treated
Data N/A: item was first used for 2010 diagnoses	25,751	50.3%
Endoscopic or laparoscopic converted to open	130	0.3%
Endoscopic or laparoscopic	399	0.8%
No surgical procedure of primary site at this facility	4,084	8.0%
Open or approach unspecified	20,668	40.4%
Robotic assisted	99	0.2%
Robotic converted to open	13	0.0%
Total (ALL)	51,144	100.0%

Source: The National Cancer Data Base (NCDB) of the American College of Surgeons (ACS), 2004-2015.